Drug Profile
Tildacerfont - Spruce Biosciences
Alternative Names: SPR 001Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Spruce Biosciences
- Class 2 ring heterocyclic compounds; Morpholines; Pyrazoles; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Congenital adrenal hyperplasia; Polycystic ovary syndrome
Most Recent Events
- 14 Mar 2024 Updated efficacy data from a phase II CAHmelia-203 trial in congenital adrenal hyperplasia released by Spruce Biosciences
- 14 Mar 2024 Spruce Biosciences terminates phase II CAHmelia-203 trial in Congenital Adrenal Hyperplasia in US, Australia, Canada, Italy, Poland, Spain, UK, the Netherlands, Sweden, Germany, Estonia, South Korea, Latvia, Switzerland, Lithuania, Brazil, Romania, Ireland, Turkey and Denmark
- 14 Mar 2024 Adverse events data from a phase II CAHmelia-203 trial in Congenital Adrenal Hyperplasia released by Spruce Biosciences